AMB-051 is under clinical development by AmMax Bio and currently in Phase II for Tenosynovial Giant Cell Tumor. According to GlobalData, Phase II drugs for Tenosynovial Giant Cell Tumor have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AMB-051’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AMB-051 overview

AMB-051 is under development for the treatment of tenosynovial giant cell tumor of the knee, advanced solid tumors such as tenosynovial giant cell tumor of the knee, pancreatic cancer, colorectal cancer, non small cell lung cancer, diabetic macular edema, age related macular degeneration and polycystic kidney disease. It is administered intravenously as a concentrate for a solution. It is a fully human IgG2 monoclonal antibody against the colony-stimulating factor-1 (CSF-1 or M-CSF) receptor c-fms (CSFR1).

It was also under development for the treatment of idiopathic pulmonary fibrosis.

For a complete picture of AMB-051’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.